根据新的证据, FDA 删除了更年期激素治疗标签中的关键警告. FDA removes key warnings from menopausal hormone therapy labels based on new evidence.

林业发展局核准了六种更年期激素治疗产品的最新标签,删除了有关心血管疾病、乳腺癌和可能痴呆症的箱式警告。 The FDA has approved updated labels for six menopausal hormone therapy products, removing boxed warnings about cardiovascular disease, breast cancer, and probable dementia. 根据对现有证据的审查,这一变化旨在提供更准确、更平衡的信息,以帮助妇女作出知情决定。 The change, based on a review of current evidence, aims to provide more accurate, balanced information to help women make informed decisions. 更新的标签适用于用于发热,阴道干燥和骨质损失的全身和局部HRT选择. The updated labels apply to systemic and topical HRT options used for hot flashes, vaginal dryness, and bone loss. 美国食品和药物管理局指出,在更年期10年内开始接受HRT的女性可能死亡率和骨折风险较低. The FDA noted that women starting HRT within 10 years of menopause may have lower mortality and fracture risk. 卫生官员强调与提供者讨论各种选择方案。 Health officials emphasize discussing options with providers.